Thiosemicarbazone-Based Compounds: A Promising Scaffold for Developing Antibacterial, Antioxidant, and Anticancer Therapeutics

Overview

Journal Molecules

Publisher MDPI

Date 2025 Jan 11

PMID 39795184

Authors

Agnieszka Czylkowska

Monika Pitucha

Anita Raducka

Ewelina Fornal

Edyta Kordialik-Bogacka

Sylwia Scieszka

Marek Smoluch

Franciszek Burdan

Mateusz Jedrzejec

Pawel Szymanski

Affiliations

Soon will be listed here.

Abstract

This paper presents the synthesis and characterization of new thiosemicarbazone derivatives with potential applications as antibacterial, antioxidant and anticancer agents. Six thiosemicarbazone derivatives (L-L5) were synthesized by reacting an appropriate thiosemicarbazide derivative with 2-pyridinecarboxaldehyde. The structures of the obtained compounds were confirmed using mass spectrometry, infrared spectroscopy, and NMR spectroscopy. Antibacterial activity was evaluated by using the microdilution method, determining the minimum inhibitory concentration (MIC) against a panel of Gram-positive and Gram-negative bacteria. Compound L1 showed the most potent antibacterial activity, especially against (MIC 10 mg/L). Molecular docking to topoisomerase II and transcriptional regulator PrfA suggests that the studied compounds can effectively bind to molecular targets recognized in anticancer and antibacterial therapies. An assessment of physicochemical properties (ADME) indicates favorable parameters of the compounds as potential drugs. Compounds L and L2 showed the highest antioxidant activity, surpassing the activity of the Trolox standard. Cytotoxicity against A549 lung cancer cells was evaluated by the MTT assay. Compound L4 exhibited the strongest inhibitory effect on cancer cell survival. The obtained results indicate that the synthesized thiosemicarbazide derivatives, especially L1, L2, and L4, are promising compounds with potential applications as antibacterial and anticancer drugs.

References

Saeed K, Rafiq M, Khalid M, Hussain A, Siddique F, Hanif M . Synthesis, characterization, computational assay and anti-inflammatory activity of thiosemicarbazone derivatives: Highly potent and efficacious for COX inhibitors. Int Immunopharmacol. 2023; 126:111259. DOI: 10.1016/j.intimp.2023.111259. View

Wos M, Miazga-Karska M, Kaczor A, Klimek K, Karczmarzyk Z, Kowalczuk D . Novel thiosemicarbazide derivatives with 4-nitrophenyl group as multi-target drugs: α-glucosidase inhibitors with antibacterial and antiproliferative activity. Biomed Pharmacother. 2017; 93:1269-1276. DOI: 10.1016/j.biopha.2017.07.049. View

Reshi Z, Ahmad W, Lukatkin A, Javed S . From Nature to Lab: A Review of Secondary Metabolite Biosynthetic Pathways, Environmental Influences, and In Vitro Approaches. Metabolites. 2023; 13(8). PMC: 10456650. DOI: 10.3390/metabo13080895. View

Veber D, Johnson S, Cheng H, Smith B, Ward K, Kopple K . Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002; 45(12):2615-23. DOI: 10.1021/jm020017n. View

Sagnou M, Mavroidi B, Kaminari A, Boukos N, Pelecanou M . Novel Isatin Thiosemicarbazone Derivatives as Potent Inhibitors of β-Amyloid Peptide Aggregation and Toxicity. ACS Chem Neurosci. 2020; 11(15):2266-2276. DOI: 10.1021/acschemneuro.0c00208. View

Jones G, Willett P, Glen R, Leach A, Taylor R . Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997; 267(3):727-48. DOI: 10.1006/jmbi.1996.0897. View

Giske C, Turnidge J, Canton R, Kahlmeter G . Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). J Clin Microbiol. 2021; 60(3):e0027621. PMC: 8925892. DOI: 10.1128/JCM.00276-21. View

Laxmi S, Rajitha G, Rajitha B, Rao A . Photochemical synthesis and anticancer activity of barbituric acid, thiobarbituric acid, thiosemicarbazide, and isoniazid linked to 2-phenyl indole derivatives. J Chem Biol. 2016; 9(2):57-63. PMC: 4830754. DOI: 10.1007/s12154-015-0148-y. View

Li M, Chen C, Ling C, Zhou J, Ji B, Wu Y . Cytotoxicity and structure-activity relationships of four alpha-N-heterocyclic thiosemicarbazone derivatives crystal structure of 2-acetylpyrazine thiosemicarbazone. Bioorg Med Chem Lett. 2009; 19(10):2704-6. DOI: 10.1016/j.bmcl.2009.03.135. View

10.

Groom C, Bruno I, Lightfoot M, Ward S . The Cambridge Structural Database. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016; 72(Pt 2):171-9. PMC: 4822653. DOI: 10.1107/S2052520616003954. View

11.

Ayoup M, Wahby Y, Abdel-Hamid H, Abu-Serie M, Ramadan S, Barakat A . Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer. RSC Adv. 2023; 13(40):27722-27737. PMC: 10509784. DOI: 10.1039/d3ra04029a. View

12.

Umamatheswari S, Balaji B, Ramanathan M, Kabilan S . Synthesis, stereochemistry, antimicrobial evaluation and QSAR studies of 2,6-diaryltetrahydropyran-4-one thiosemicarbazones. Eur J Med Chem. 2011; 46(4):1415-24. DOI: 10.1016/j.ejmech.2011.01.029. View

13.

Thanh Nguyen D, Le T, Trang Bui T . Antioxidant activities of thiosemicarbazones from substituted benzaldehydes and N-(tetra-O-acetyl-β-D-galactopyranosyl)thiosemicarbazide. Eur J Med Chem. 2013; 60:199-207. DOI: 10.1016/j.ejmech.2012.10.004. View

14.

Pitucha M, Korga-Plewko A, Czylkowska A, Rogalewicz B, Drozd M, Iwan M . Influence of Complexation of Thiosemicarbazone Derivatives with Cu (II) Ions on Their Antitumor Activity against Melanoma Cells. Int J Mol Sci. 2021; 22(6). PMC: 8002893. DOI: 10.3390/ijms22063104. View

15.

dilovic I, Rubcic M, Vrdoljak V, Kraljevic Pavelic S, Kralj M, Piantanida I . Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity. Bioorg Med Chem. 2008; 16(9):5189-98. DOI: 10.1016/j.bmc.2008.03.006. View

16.

Sever B, Altintop M, Ciftci G, Ozdemir A . A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, In silico and In vitro Studies Providing Mechanistic Insight into Their Anticancer Potencies. Med Chem. 2020; 17(10):1104-1128. DOI: 10.2174/1573406416666201021142832. View

17.

Chen R, Huo L, Jaiswal Y, Huang J, Zhong Z, Zhong J . Design, Synthesis, Antimicrobial, and Anticancer Activities of Acridine Thiosemicarbazides Derivatives. Molecules. 2019; 24(11). PMC: 6600397. DOI: 10.3390/molecules24112065. View

18.

Verdonk M, Cole J, Hartshorn M, Murray C, Taylor R . Improved protein-ligand docking using GOLD. Proteins. 2003; 52(4):609-23. DOI: 10.1002/prot.10465. View

19.

Vandresen F, Falzirolli H, Almeida Batista S, da Silva-Giardini A, de Oliveira D, Catharino R . Novel R-(+)-limonene-based thiosemicarbazones and their antitumor activity against human tumor cell lines. Eur J Med Chem. 2014; 79:110-6. DOI: 10.1016/j.ejmech.2014.03.086. View

20.

Nitiss J . Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009; 9(5):338-50. PMC: 2748742. DOI: 10.1038/nrc2607. View